Abstract Tuberculosis (TB), particularly drug-resistant tuberculosis (DR-TB), remains a critical global challenge and underscores the urgent need for novel drugs and innovative combination regimens with distinct mechanisms of action. Here, we characterize an all-oral three-drug regimen comprising TBI-166, bedaquiline(BDQ), and pyrazinamide(PZA), which displays strong synergistic antimicrobial activity in vitro against both replicating and non-replicating Mycobacterium tuberculosis (MTB) and has previously shown superior bactericidal and sterilizing efficacy to standard HRZ and BPaL regimens in murine TB models(1). Time-kill studies demonstrate that the triple regimen outperforms dual-drug combinations, accelerating bacterial clearance across multiple physiological states. Mechanistic investigations revealed that the TBI-166–BDQ–PZA combination induces a comprehensive collapse of energy and redox homeostasis, marked by profound ATP depletion, robust accumulation of reactive oxygen species (ROS), and marked disruption of the intracellular NAD(H) pool. TBI-166, a novel riminophenazine analogue of clofazimine (CFZ) currently in phase II clinical trials, emerged as a key contributor to this metabolic stress. Metabolomic profiling and ¹³C-based flux analysis show that TBI-166 slows glycolysis and the tricarboxylic acid (TCA) cycle while enhancing flux through the pentose phosphate and nicotinate pathways, thereby lowering the NADH/NAD⁺ ratio and diminishing MTB metabolic flexibility under environmental stress. In parallel, TBI-166 downregulates the dormancy regulator DosR and its regulon, further compromising adaptation to non-replicating states. Multi-omics analyses, together with biochemical and biophysical assays, identify the pyruvate dehydrogenase complex (PDHc) components DlaT and LpdC as direct molecular targets of TBI-166, with drug binding leading to potent inhibition of their enzymatic activities. Collectively, these findings define the mechanism of action of TBI-166 and provide a molecular rationale for its inclusion in potent, all-oral, short-course regimens. More broadly, they highlight the therapeutic potential of metabolically targeted combinations that destabilize energy metabolism, redox balance, and metabolic adaptability to improve DR-TB treatment outcomes.

Neurodegenerative diseases (NDs) pose a significant public health concern due to their association with cognitive impairment and disrupted brain glucose metabolism. Cyanidin 3-O-beta-galactoside (Cy3Gal), an anthocyanin from black chokeberry, exerted neuroprotective effects by modulating brain energy metabolism. This study aims to investigate its absorption, tissue distribution, and metabolic profile. Following a single-dose administration (gavage, 300 mg/kg) to male Sprague-Dawley rats, Cy3Gal reached a peak plasma concentration of 2967.29 +/- 556.71 ng/mL within 0.25 h. Pharmacokinetic analysis revealed a short half-life (0.77 +/- 0.05 h) and high clearance rate (101.84 +/- 23.90 L/h/kg), suggesting a fast distribution and elimination. Twenty metabolites were identified in plasma, including methylated, glucuronidated, and sulfated forms, with varying distribution across rat tissues. Notably, this is the first study to demonstrate that Cy3Gal and its methylated metabolites (peonidin 3-O-galactoside [Peo3Gal]) can cross the blood-brain barrier, which provided strong evidence for the neuroprotective effects. Peo3Gal showed superior protection against high glucose-induced injury compared to Cy3Gal. Additionally, in vitro fermentation with rat gut microbiota uncovered three Cy3Gal-derived metabolites, suggesting microbial involvement in its transformation. Overall, these findings provide critical insights into Cy3Gal's bioavailability and brain accessibility, supporting its potential as a dietary neuroprotective agent.

OBJECTIVES:NTB-3119M, a novel benzothiopyranone derivative identified through comprehensive drug development studies, was selected as a promising antituberculosis (anti-TB) candidate. This study systematically evaluated its anti-TB efficacy in vitro and in vivo. METHODS:In vitro analyses encompassed antimicrobial susceptibility testing to determine minimum inhibitory concentrations (MICs) against Mycobacterium tuberculosis H37Rv, 10 drug-susceptible clinical isolates, and 30 multidrug-resistant (MDR) strains, alongside evaluations of minimal bactericidal concentrations (MBCs) using H37Rv and seven clinical isolates. Additionally, intracellular anti-mycobacterial activity was assessed in H37Rv-infected macrophages, and cytotoxicity was profiled through MTT assays on Vero cells. In vivo studies utilized acute and chronic murine tuberculosis infection models to investigate the dose-dependent efficacy of NTB-3119M (50 and 100 mg/kg) against H37Rv, with concurrent comparative histopathological analysis of lung and spleen tissues. RESULTS:NTB-3119M demonstrated superior in vitro potency against both drug-sensitive and drug-resistant M. tuberculosis strains compared to first-line agents, Isoniazid (INH), Rifampicin (RIF), Moxifloxacin (MOFX), Levofloxacin (LVFX), and Streptomycin (SM), exhibiting comparable activity to PBTZ169. Time-kill curves for NTB-3119M indicate its potent bactericidal activity. Meanwhile, No cytotoxicity was observed on Vero cells. Spontaneous resistant mutants of NTB-3119M appears at a frequency of 6.44 × 10-7 to 3.65 × 10-6. Most importantly, NTB-3119M demonstrates comparable activity of PBTZ169 and better bactericidal activity against M. tuberculosis than INH and RIF in the 50- and 100- mg/kg groups in acute and chronic murine models. CONCLUSION:Our research provided comprehensive evidence that NTB-3119M with increased water solubility and bioavailability based on previous research performed excellent anti-tuberculosis activity and less cytotoxicity, which effectively tackled the undesirable drug properties associated with previous benzothiopyrone derivatives. It is warranted that NTB-3119M, as a highly promising candidate anti tuberculosis drug, deserves further research and clinical trial.

Unhealthy diets are associated with various diseases that can disrupt brain energy metabolism, which significantly increased the risk of cognitive impairment and chronic neurodegenerative diseases. Early intervention with nutritional supplements may have long-lasting positive effects on diet-related glucose metabolism and potentially mediate the progression of neurodegeneration in middle-aged and elderly people. We previously reported that cyanidin 3-O-u03B2-galactoside (Cy3Gal), an anthocyanin from black chokeberry (Aronia melanocarpa (Michx.) Elliott), alleviated cognitive impairment in aging mice through regulating brain energy metabolism. However, it remains unclear whether Cy3Gal can also exert beneficial effects in mice fed with a high-fat/high-sugar diet. Here we revealed that Cy3Gal treatment conserved the health of neurons and synapses, as well as cognitive function of mice. Furthermore, we observed that Cy3Gal effectively improved glucose uptake and metabolism of skeletal muscle by enhancing glycolysis both in vivo and in vitro models, which is essential for maintaining a stable glucose supply to the brain. Additionally, Cy3Gal significantly increased the levels of glucose-derived tricarboxylic acid cycle intermediates in the mice brain (P u0026lt; 0.05), and regulated the activities of mitochondrial respiratory chain complexes (P u0026lt; 0.01). The positive influence on peripheral and brain bioenergetics explained how the Cy3Gal exerted neuroprotective effect. In conclusion, our study illustrated that early dietary intervention of Cy3Gal had significant advantages in terms of neuroprotection and cognition under the challenge of HFHS diet-induced glucose metabolism disorder.

Objective We measured cerebral venous oxygenation after aneurysmal subarachnoid hemorrhage (aSAH) using quantitative susceptibility mapping (QSM) to explore its relationship with cognitive function. Methods Twenty participants, including 10 patients with aSAH and 10 healthy volunteers as the control group, were included. Patients with aSAH were evaluated at 2 days, 3 weeks, and 6 months after aSAH. Each participant underwent magnetic resonance imaging and completed the Montreal Cognitive Assessment (MoCA) at baseline, midpoint, and endpoint. QSM was used to determine the magnetic susceptibility of the cerebral veins. Furthermore, the relationship between MoCA and oxygen saturation in the cerebral veins was examined. Results The first scans of the cerebral veins and straight sinus susceptibility were considerably more significant in the aSAH group than in the healthy control group. At the 6-month follow-up, the mean oxygen saturation steadily increased in the aSAH group. Cerebral venous oxygen saturation was moderately correlated with MoCA (r = 0.5319, P = .0025). Conclusion QSM can be used to measure changes in cerebral venous oxygenation levels in patients with aSAH. During the acute phase of aSAH, there is a reduction in the oxygen saturation in the cerebral veins, and the shift in oxygen saturation levels may correlate with cognitive outcomes in patients with aSAH.

Porcine reproductive and respiratory syndrome (PRRS) is associated with the endemic outbreak of fever, anorexia, and abortion in pregnant sows, resulting in an enormous economic impact on the global swine industry. Current mainstream prophylactic agents and therapies have been developed to prevent PRRSV infection; however, they have limited efficacy. Therefore, there is an urgent need to develop novel antiviral strategies to prevent PRRSV infection and transmission. The identification of new PRRSV entry mediators, such as MYH9 and HSPA8; viral apoptotic mimicry; and TIM-induced macropinocytosis, to facilitate infection has led to a novel molecular understanding of the PRRSV infection mechanism, which can be utilized in the development of prophylactic agents and therapies for PRRSV infection. Polyphenols, complex chemical molecules with abundant biological activities derived from microorganisms and plants, have demonstrated great potential for controlling PRRSV infection via different mechanisms. To explore new possibilities for treating PRRSV infection with polyphenols, this review focuses on summarizing the pathogenesis of PRRSV, reviewing the potential antiviral mechanisms of polyphenols against PRRSV, and addressing the challenges associated with the widespread use of polyphenols.

医院制剂生产有着严格的生产工艺流程,从原辅料、中间品到最终上市的制剂,都要求记录批号、数量、重量、时间、人员、设备参数、偏差等相关数据,这是保证制剂质量的根本依据.本文以首都医科大学附属北京世纪坛医院(以下简称"我院")制剂中心为例,在医疗机构制剂配制管理规程的基础上,建设了一套完整制剂生产管理系统,并应用于控制我院制剂维生素E乳膏的生产过程中.通过生产管理系统中的信息化手段,有效整合制剂生产各个环节中的数据并完整记录,有效地解决了溯源问题,最终实现了制剂生产的全过程管理,保证了制剂质量.

Clofazimine (CFZ) has been repurposed for treating tuberculosis (TB), especially multidrug-resistant tuberculosis (MDR-TB). However, the mechanisms of resistance to clofazimine are poorly understood. We previously reported a mutation located in the intergenic region of Rv1453 that was linked to resistance to CFZ and demonstrated that an Rv1453 knockout resulted in an increased minimum inhibitory concentration (MIC) of CFZ. The current study aims to go back and describe in detail how the mutation was identified and further explore its association with CFZ resistance by testing additional 30 isolates. We investigated MICs of clofazimine against 100 clinical strains isolated from MDR-TB patients by microplate alamarBlue assay. Whole-genome sequencing (WGS) was performed on 11 clofazimine-resistant and 7 clofazimine-susceptible strains, including H37Rv. Among the 11 clofazimine-resistant mutants subjected to WGS, the rate of mutation in the intergenic region of the Rv1453 gene was 55% (6/11) in clofazimine-resistant strains. Among another 30 clofazimine-resistant clinical isolates, 27 had mutations in the intergenic region of the Rv1453 gene. A mutation in the Rv1453 gene associated with clofazimine resistance was identified, which shed light on the mechanisms of action and resistance of clofazimine. IMPORTANCE Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium tuberculosis, especially the emergence of multidrug-resistant tuberculosis (MDR-TB) brings great distress to humans. Clofazimine (CFZ) plays an important role in the treatment of MDR-TB. To understand the underlying mechanism of clofazimine resistance better, in this study, we review and detail the findings of the mutation of intergenic region of Rv1453 and find additional evidence that this mutation is related to clofazimine resistance in 30 additional isolates. The significance of our research is to contribute to a comprehensive understanding of clofazimine-resistant mechanisms, which is critical for reducing the emergence of resistance and for anti-TB drug discovery.

Berberine, palmatine, physcion, rhein, calycosin-7-O-glucoside, and ferulic acid are six major active consituents that are present in Gushen Jiedu capsule (GSJD) extracts. The aim of this study was to determine the pharmacokinetics of the six active consituents in vivo by a rapid, sensitive, and precise UPLC-MS/MS method, which were compared between normal and diabetic nephropathy (DN) rats. Good separation of the target analytes and internal standards (ketoprofen and puerarin) was obtained on a Waters BEH C-18 UPLC column with a mobile phase of 0.1 % formic acid acetonitrile-0.1 % formic acid water. All the calibration curves showed good linearity with a regression coefficient (r(2)) of = 0.9908. The lower limits of quantification (LLOQ) for berberine, palmatine, physcion, rhein, calycosin-7-O-glucoside, and ferulic acid were 20, 2.5, 20, 20, 2.5, and 2.5 ng/mL, respectively. The relative standard deviations (RSDs) of intra-day and inter-day precision were all within 12.66 %, and the relative errors of intra-day and inter-day accuracy ranged from -15.00 to 14.93 %. Good extraction recovery and matrix effects were obtained. The stability study confirmed the stability of the six analytes (RSD < 15 %). Finally, the data showed that the pharmacokinetic parameters (especially CLz/F, AUC and T-max) of the six target analytes in DN rats were significantly different from those in normal rats. PK studies under pathological conditions could provide new thoughts to elucidate the underlying mechanism of GSJD and promote the clinical development of GSJD to treat DN.

BACKGROUND Antipsychotics are associated with abnormalities in glucose metabolism in patients with schizophrenia. Liraglutide, a GLP-1 receptor agonist, is Food and Drug Administration approved for the treatment of type 2 diabetes mellitus. However, ways to maintain the long-term stability of psychotic symptoms and balance the disadvantages of obesity, diabetes, and other metabolic disorders caused by antipsychotic medications remain unclear. In this study, we present a case of weight gain and hyperglycemia in a schizophrenia patient who received antipsychotic polypharmacy for 6 years. CASE SUMMARY A 27-year-old man with olanzapine and sodium valproate-treated disorganized schizophrenia was admitted to a diabetes outpatient clinic. He was diagnosed with type 2 diabetes (fasting blood glucose, 20 mmol/L) and obesity (body mass index, 38.58 kg/m(2)). The patient had been treated with glargine (40 IU/d) and metformin (1.5 g/d) and showed a poor response for 2 mo. Two years of liraglutide treatment resulted in stable blood glucose levels and weight loss in addition to a maintained stable mental status for a long time. The biological activities of GLP-1 significantly improved glucose levels and body weight in the schizophrenia patient treated with antipsychotic medications. CONCLUSION Liraglutide administration can be considered an effective alternative treatment for abnormalities in glucose metabolism in schizophrenia patients receiving antipsychotics.

目的 分析北京市新生儿血流感染(bloodstream infection)致病菌分布及耐药特征,为临床合理使用抗生素提供依据.方法 对2016-2020年首都医科大学附属北京地坛医院新生儿血流感染患儿血培养标本,用细菌鉴定、药物敏感试验对其致病菌及耐药特征分析.结果 新生儿血培养标本4 746份,阳性标本218份,阳性率4.59％.阳性标本共分离致病菌218株,革兰阴性菌(Gram-negative bacteria)124株,占56.88％;革兰阳性菌(Gram-positive bacteria)81株,占37.16％.致病菌以肺炎克雷伯菌(Klebsiella pneumoniiae)和大肠埃希菌(Escherichiat coli)为主,分别占总阳性样本的27.52％和26.15％.早发型感染组致病菌以B族链球菌与大肠埃希菌为主,分别占34.21％、21.05％;晚发型感染组则以肺炎克雷伯菌与大肠埃希菌为主,分别占31.11％、27.22％.B族链球菌(group B Strepto-coccus,GBS)对青霉素与氨节西林完全敏感;金黄色葡萄球菌(Staphylococcus aureus)对头孢哌酮/舒巴坦耐药率较低;肺炎克雷伯菌和大肠埃希菌对亚胺培南的耐药率均较低.结论 新生儿血流感染致病菌以革兰阴性菌为主,早发型与晚发型感染主要致病菌有所差异.建议经验性治疗B族链球菌感染用青霉素或氨苄西林,金黄色葡萄球菌推荐使用含β-内酰胺酶抑制剂的头孢菌素,而革兰阴性菌则首选亚胺培南.

Ocean-based chitin biomass refinery has gained growing attentions for the renewable production of various nitrogenous chemicals. Herein, a green, simple and efficient approach was put forward to obtain valuable glucosaminic acid (GlcNA) from chitin-derived glucosamine (GlcN) in water under near room temperature and atmospheric air. The highest GlcNA yield of ~85% was achieved under optimal conditions by gold nanoparticles on zinc oxide (Au/ZnO) fabricated by a deposition precipitation (DP) method, without the extra addition of any base or oxidant. The richer surface oxygen vacancies on ZnO was beneficial to generate well-dispersed Au NPs compared to other attempted support species. Au NPs with varied average particle sizes were synthesized by adjusting the catalyst preparation methods and parameters. A good linear relationship was established between TOFs and 1/d, which shows that small-sized (1.5-2 nm), uniformly-dispersed Au NPs on ZnO was important for GlcN oxidation under mild conditions. This study points out a useful direction to improve the oxidative activity of supported Au catalysts and opens new possibilities for mild but effective exploitation of chitin biomass.

目的 分析抗凝血酶Ⅲ活性联合慢性肝功能衰竭联盟—器官功能衰竭评分(CLIF-C OFs)对乙型肝炎病毒相关慢加急性肝衰竭(HBV-ACLF)患者预后的评估价值.方法 选取2019年8月—2021年5月首都医科大学附属北京安贞医院急诊危重症中心收治HBV-ACLF患者243例,根据病情严重程度分为早期组(n=107)、中期组(n=63)、晚期组(n=73),并根据患者60 d预后情况分为死亡组(n=53)和存活组(n=190).发色底物法检测患者入院时的抗凝血酶Ⅲ活性,并计算入院时的CLIF-C OFs评分.多因素Logistic回归分析HBV-ACLF患者预后不良的影响因素,ROC曲线分析抗凝血酶Ⅲ活性联合CLIF-C OFs评分对HBV-ACLF患者预后不良的评估价值.结果 早期组、中期组、晚期组患者的抗凝血酶Ⅲ活性依次降低,CLIF-C OFs评分依次升高(H=195.003、139.852,P均<0.01).与存活组比较,死亡组CLIF-C OFs评分、中性粒细胞比值、总胆红素、乙肝表面抗原(HBsAg)升高,抗凝血酶Ⅲ活性降低(Z/t=6.712、2.691、2.692、3.166、6.234,P=0.000、0.008、0.008、0.002、0.000).高中性粒细胞比值、高HBsAg、高CLIF-C OFs评分为HBV-ACLF患者预后不良的独立危险因素[OR(95％CI)=1.048(1.005～1.092)、1.866(1.200～3.481)、2.850(2.011～4.039)],高抗凝血酶Ⅲ活性为独立保护因素[OR(95％CI)=0.848(0.785～0.917)].抗凝血酶Ⅲ活性、CLIF-C OFs评分及二者联合评估HBV-ACLF患者预后不良的曲线下面积(AUC)为0.780、0.787、0.878,二者联合预测大于单独评估(Z=3.655、2.912,P=0.000、0.004).结论 抗凝血酶Ⅲ活性降低和CLIF-C OFs评分升高与HBV-ACLF患者病情加重和预后不良相关,抗凝血酶Ⅲ活性联合CLIF-C OFs评分能提升对HBV-ACLF患者预后不良的评估价值.

Cyclic adenosine monophosphate (cAMP) has received considerable attention because it naturally occurs in jujube fruit and possesses many activities such as antitumor activity. However, its poor membrane permeability limits its applications in food industry. In this study, we found that polysaccharides likewise derived from jujube (ZJP) are able to increase the membrane permeability of cAMP for the first time. To elucidate the mechanism, the interactions of cAMP and ZJP were determined by spectroscopic, thermodynamic and molecular docking methods. Results showed that acidic polysaccharide (ZJPA) owned a stronger affinity to cAMP as compared to neutral polysaccharide (ZJPN). Consequently, the binding of ZJPA to cAMP existed a better synergistic antioxidant capacity and also protected ZJPA against pH-induced degradation. More importantly, the formed ZJPA-cAMP complexes exhibited much better bio-accessibility than unbound cAMP as was approved by Caco-2 cell absorption experiment. These new findings are beneficial for designing polysaccharide-based nanocarriers for cAMP.

目的 探讨超声造影检查方法对颅外段颈内动脉次全闭塞的评估价值.方法 本研究回顾性分析经常规超声诊断为颈内动脉闭塞并行超声造影检查的39名患者临床资料.结果 经常规超声诊断为颅外段颈内动脉管腔完全闭塞的39条颈内动脉中,32条(82％)超声造影诊断为次全闭塞,7条(18％)为真性闭塞.在超声造影诊断的32条颅外段颈内动脉次全闭塞患者,其中20条(62.5％)为节段性次全闭塞,12条(37.5％)为弥漫性次全闭塞.结论 超声造影可以高度灵敏地检出颅外段颈内动脉次全闭塞,并且根据其管腔内血流特点,将其分为节段性次全闭塞和弥漫性次全闭塞,为临床治疗和预后提供重要信息.

目的:评价吡法齐明(pyrifazimine,TBI-166)与贝达喹啉(bedaquiline,Bdq)、莫西沙星(moxifloxacin,Mfx)、德拉马尼(delamanid,Dlm)、SQ109及PBTZ169的两药组合对结核分枝杆菌(MTB)临床分离株的相互作用,并初步探讨TBI-166与Bdq的协同作用机制,为TBI-166联合用药提供依据.方法:选取MTB标准株H37Rv(ATCC 27294)、2株药物敏感型MTB临床分离株(菌株编号:30031和30091),以及1株前广泛耐药结核分枝杆菌临床分离株(菌株编号:13385),应用棋盘法测定TBI-166与Bdq、Mfx、Dlm、SQ109、PBTZ169两药组合对临床分离菌株的相互作用;应用时间杀菌曲线法评估具有协同作用的两药组合的抗菌活性;采用细菌活性氧(ROS)检测试剂盒及三磷酸腺苷(ATP)检测试剂盒分别测定不同浓度的TBI-166和Bdq处理H37Rv标准株24 h后菌体内的ROS及ATP水平的变化.结果:与Bdq联用后,TBI-166对MTB临床分离株30031、30091及13385的最低抑菌浓度(minimum inhibitory concentration,MIC)分别为 0.08、0.05、0.08 μg/ml,均降至 TBI-166 单药 MIC 值的 1/2.TBI-166 与 Bdq 的两药组合对菌株 30031、30091 及 13385 的分级抑菌浓度指数(fractional inhibitory concentration index,FICI)值分别为1.00、0.75、1.00.时间杀菌曲线法结果显示,TBI-166与Bdq的两药组合与菌株30031、30091及13385作用14 d后与TBI-166单药应用时相比活菌量分别减少1.59 logi0 CFU/ml、1.27 log10 CFU/ml、1.70 log10 CFU/ml.0.4 μg/ml TBI-166 与 0.3 μg/ml Bdq 联用作用于 H37Rv 标准株 24 h 后菌体内 ATP 含量(相对光单位值为115 160.67±19 129.79)与0.3 μg/ml Bdq(相对光单位值为208 599.20±24 078.74)相比,明显下降,差异有统计学意义(F=75.109,P=0.013);而ROS含量(荧光值为21 014.33±1189.19)与0.3 μg/ml Bdq(荧光值为13 715.00+907.93)相比明显升高,差异有统计学意义(F=115.403,P＜0.001).结论:TBI-166与Bdq联用具有协同杀菌活性,并且其协同杀菌机制可能与ROS进一步累积及ATP合成受阻有关.

目的 应用常规彩色多普勒超声及超声造影技术评价颈动脉粥样硬化斑块(CASP)易损性及其对缺血性脑卒中事件的预测价值.方法 对164例患者(包括143例缺血性脑卒中患者)行颈动脉常规彩色多普勒超声检查,共检出260个CASP,测量斑块最大厚度后,行超声造影检查,观察斑块内新生血管位置、是否达到斑块表面、对新生血管数量进行评分.结果 CASP厚度与其内新生血管数量之间呈中度正相关,且厚度≥0.4 cm时,其内新生血管数量明显增多,且约72.7％患者患有脑卒中;若新生血管到达CASP表面,则这类斑块内新生血管数量明显多于未达到斑块表面者,且约93.7％患有脑卒中的患者位于该组;CASP肩部、基底部、顶部的新生血管数量依次递减,但CASP近心端肩部与远心端肩部的新生血管数量无统计学差异.结论 当CASP最大厚度≥0.4 cm、CASP肩部新生血管密度大且新生血管达到CASP表面时,发生缺血性脑卒中风险高.

Objective:To observe the influence of air pressure change in the hyperbaric oxygen chamber on the safety of the volumetric infusion pump operation and the accuracy of the flow rate.Methods:The instantaneous flow rate and average flow rate of the volumetric infusion pump set at the flow rates of 50 and 100 ml/h were repeatedly measured for 7 times by the real-time flow rate monitoring system under high air pressure (gauge pressure 0-0.10 MPa) and normal pressure (atmospheric pressure in Beijing), respectively. The operation status of the volumetric infusion pump in the high-pressure environment (gauge pressure 0-0.10 MPa) was observed, and the instantaneous flow rates and average flow rates of the volumetric infusion pump under both high and normal pressures were compared.Results:The volumetric infusion pump could operate smoothly, and no electrical safety accident or malfunction occurred in the scenarios of uniform pressurization and decompression and high-pressure stabilization in the hyperbaric oxygen chamber. When the flow rate of the infusion pump was set at 50 and 100 ml/h, comparing the instantaneous flow rate and average flow rate under the high pressure (gauge pressure 0-0.1 MPa) and the normal pressure environment respectively, there was no statistically significant difference ( P>0.05), and the relative indication errors of the flow were all within ±2%. Conclusion:The volumetric infusion pump can safely operate and maintain accurate flow rate (50 ml/h and 100 ml/h) in hyperbaric oxygen chamber.